Physician profile

Scott E Litwiller

Urology · Tulsa, OK

NPI 1558382028

$27,007.53

in general payments reported to CMS, 2019-2025

46 companies · $944 in 2025

The $944 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,671.10
Honoraria$257.63

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Axonics, INC. $10,975.92 2020-2024 Axonics
Astellas Pharma US INC $8,688.49 2019-2024 Xtandi
Sumitomo Pharma America, INC. $850.50 2023-2025 Gemtesa, Orgovyx
Janssen Biotech, INC. $557.93 2019-2025 Erleada
Medtronic USA, INC. $482.01 2019
Boston Scientific Corporation $450.17 2019-2025 Axonics, Advantage System
Urovant Sciences INC $430.65 2021-2022
Coloplast Corp $396.35 2020-2024 Speedicath
Pfizer INC. $393.07 2019-2025
Valencia Technologies Corporation $371.68 2022-2024 Ecoin Device Kit
Allergan, INC. $368.23 2019-2021
Merck Sharp & Dohme LLC $332.41 2020-2025 Keytruda, Lynparza, Welireg
Caldera Medical, INC $277.53 2021-2025
Bayer Healthcare Pharmaceuticals INC. $246.73 2019-2024
Tolmar Pharmaceuticals, INC. $218.30 2019-2022
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $217.49 2022-2025 Interstim
Sun Pharmaceutical Industries INC. $209.32 2019-2022
Abbvie INC. $119.18 2019-2025
Progenics Pharmaceuticals, INC. $112.86 2023 Pylarify
Verity Pharmaceuticals INC. $102.85 2023-2024 Trelstar
Dendreon Pharmaceuticals LLC $98.47 2019-2024 Provenge
Amgen INC. $95.56 2019-2023 Prolia
Endo Pharmaceuticals INC. $92.11 2020-2022
Myovant Sciences INC. $89.21 2021-2022
Accord Healthcare, INC. $79.83 2023-2024
Travere Therapeutics, INC. $78.66 2019-2021
Therapeuticsmd, INC. $74.75 2019-2022
Antares Pharma, INC. $56.06 2020-2023 Tlando, Xyosted, Nocdurna
E.R. Squibb & Sons, L.L.C. $52.04 2022-2024 Opdivo
Teleflex LLC $51.28 2022-2023 Urolift
Bluewind Medical $50.10 2024
Telix Pharmaceuticals $44.82 2025 Illuccix
Astrazeneca Pharmaceuticals LP $43.40 2020
Blue Earth Diagnostics $42.08 2022-2023
Immunitybio, INC. $41.93 2025
Novartis Pharmaceuticals Corporation $30.22 2025
Baudax Bio INC. $24.53 2021-2022
Urogen Pharma, INC. $22.92 2025
Procept Biorobotics Corporation $22.57 2020
Novo Nordisk INC $22.04 2024 Rivfloza
Alnylam Pharmaceuticals INC. $19.61 2023 Givlaari
Palette Life Sciences, INC. $18.27 2022
Rochester Medical Corporation $16.41 2021
Clarus Therapeutics INC. $15.10 2021
Duchesnay USA Incorporated $13.81 2019
Clovis Oncology, INC. $10.08 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Scott E Litwiller

$27,007.53

in general payments reported 2019-2025

Years
2019-2025
Top company
Axonics, INC.
Context
The $944 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/70175/scott-e-litwiller

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.